-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, China Resources Double Crane issued an announcement to sign the "Strategic Cooperation Agreement" and "Azvudine Tablet Entrusted Processing and Production Framework Agreement" with Real B.
Expand cooperation in the fie.
According to the "Strategic Cooperation Agreement", the two parties will use their respective advantages in talent reserves, R&D technology, e.
to carry out R&D cooperation on new products, new technologies and new processes, and actively promote the implementation of real biological innovative R&D produc.
At the same time, with the help of the marketing network of China Resources Double Crane, the medical coverage of real biological products in various terminals will be improved, and the channel value-added business will be develop.
In addition, according to the "Framework Agreement for the Entrusted Processing and Production of Azvudine Tablets", Real Bio has the ownership of Azvudine Tablets; applies for and obtains the drug registration certificate of the drug, is the holder of the marketing license, and owns the production (self-produced or Entrusted production), release and sales rights; and China Resources Double Crane has the right to audit and verify the technical data and control documents of Azvudine table.
The two parties will sign a separate entrustment contract based on the actual situation of each stage of clinical trials and approval for marketing and application of Azvudine tablets, as well as specific matters such as order planning, settlement methods, delivery deadlines and quality requirements involved in entrusted processing and producti.
Previously, there have been long-standing rumors of cooperation between the two parties, and the share price of China Resources Shuanghe has also been highly sought after by the capital mark.
After the official announcement of the cooperation, at the opening of the market on May 9, China Resources Shuanghe hit the daily limit at 316 yuan per sha.
It is worth noting that, in addition to the cooperation with Real Life, China Resources Shuanghe has just signed a strategic cooperation agreement with Shenzhen Hanyu Pharmaceutical .
, L.
(hereinafter referred to as Hanyu Pharmaceutica.
According to the agreement, both parties will list each other as important long-term partne.
In the cooperation, the marketing channels and customer resources of China Resources Shuanghe's advantageous regions will be combined with the advantageous product pipeline of Hanyu Pharmaceutical to fully expand the market, carry out product market expansion, product sales and academic promotion, and jointly build a multi-field, multi-product, The multi-dimensional cooperation model promotes the common development of the business of both parti.
The industry believes that China Resources Shuanghe frequently joins hands with other pharmaceutical companies, which reflects the current trend of leading companies in the pharmaceutical indust.
.
It is understood that since 2022, pharmaceutical companies have reached strategic cooperation very frequently, and recently, there have been news of cooperation from many pharmaceutical compani.
For example, on May 9, Wohua Medicine and Jointown signed a strategic cooperation framework agreeme.
The two parties set an annual cooperation target of 100 million yuan in 2022 and an annual cooperation target of 300 million yuan within five yea.
The cooperation content will carry out omni-channel cooperation in the whole range of cardiovascular and cerebrovascular, orthopedics, women and children, e.
Relying on the channel resources and service advantages of Jointown, the brand-name drugs of Wohua Pharmaceutical will further reach the medical market in more regions, covering Blind spot area, providing patients with more medication optio.
On May 6, China Resources Pharmaceutical, China Resources Sanjiu and Huali Pharmaceutical, a wholly-owned subsidiary of Huali Group, signed a strategic cooperation agreement and a share transfer agreeme.
According to the content of the agreement, the three parties will carry out strategic cooperation in traditional Chinese medicine, big health industry and other related industries to jointly expand the global mark.
On April 28, Kain Technology announced that it has signed a strategic agreement with Saifu Pharmaceutical, a one-stop CRO service provider for innovative dru.
The two parties will establish a long-term and strategic business partnership to promote the common development of innovative R&D busine.
It is reported that Kain Technology is a biopharmaceutical company that uses biotechnology as a platform, focuses on the field of viruses and immune diseases, and is committed to providing prevention and treatment solutio.
The industry said that the strategic cooperation between strong and strong can more effectively ensure the rapid advancement of the precise research and development of new drugs, improve the efficiency of new drug research and development for pharmaceutical companies, and save cos.
From the perspective of the cooperation partners sought by pharmaceutical companies this year, innovative drugs, big health, and AI are all areas that pharmaceutical companies focus .
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Expand cooperation in the fie.
According to the "Strategic Cooperation Agreement", the two parties will use their respective advantages in talent reserves, R&D technology, e.
to carry out R&D cooperation on new products, new technologies and new processes, and actively promote the implementation of real biological innovative R&D produc.
At the same time, with the help of the marketing network of China Resources Double Crane, the medical coverage of real biological products in various terminals will be improved, and the channel value-added business will be develop.
In addition, according to the "Framework Agreement for the Entrusted Processing and Production of Azvudine Tablets", Real Bio has the ownership of Azvudine Tablets; applies for and obtains the drug registration certificate of the drug, is the holder of the marketing license, and owns the production (self-produced or Entrusted production), release and sales rights; and China Resources Double Crane has the right to audit and verify the technical data and control documents of Azvudine table.
The two parties will sign a separate entrustment contract based on the actual situation of each stage of clinical trials and approval for marketing and application of Azvudine tablets, as well as specific matters such as order planning, settlement methods, delivery deadlines and quality requirements involved in entrusted processing and producti.
Previously, there have been long-standing rumors of cooperation between the two parties, and the share price of China Resources Shuanghe has also been highly sought after by the capital mark.
After the official announcement of the cooperation, at the opening of the market on May 9, China Resources Shuanghe hit the daily limit at 316 yuan per sha.
It is worth noting that, in addition to the cooperation with Real Life, China Resources Shuanghe has just signed a strategic cooperation agreement with Shenzhen Hanyu Pharmaceutical .
, L.
(hereinafter referred to as Hanyu Pharmaceutica.
According to the agreement, both parties will list each other as important long-term partne.
In the cooperation, the marketing channels and customer resources of China Resources Shuanghe's advantageous regions will be combined with the advantageous product pipeline of Hanyu Pharmaceutical to fully expand the market, carry out product market expansion, product sales and academic promotion, and jointly build a multi-field, multi-product, The multi-dimensional cooperation model promotes the common development of the business of both parti.
The industry believes that China Resources Shuanghe frequently joins hands with other pharmaceutical companies, which reflects the current trend of leading companies in the pharmaceutical indust.
.
It is understood that since 2022, pharmaceutical companies have reached strategic cooperation very frequently, and recently, there have been news of cooperation from many pharmaceutical compani.
For example, on May 9, Wohua Medicine and Jointown signed a strategic cooperation framework agreeme.
The two parties set an annual cooperation target of 100 million yuan in 2022 and an annual cooperation target of 300 million yuan within five yea.
The cooperation content will carry out omni-channel cooperation in the whole range of cardiovascular and cerebrovascular, orthopedics, women and children, e.
Relying on the channel resources and service advantages of Jointown, the brand-name drugs of Wohua Pharmaceutical will further reach the medical market in more regions, covering Blind spot area, providing patients with more medication optio.
On May 6, China Resources Pharmaceutical, China Resources Sanjiu and Huali Pharmaceutical, a wholly-owned subsidiary of Huali Group, signed a strategic cooperation agreement and a share transfer agreeme.
According to the content of the agreement, the three parties will carry out strategic cooperation in traditional Chinese medicine, big health industry and other related industries to jointly expand the global mark.
On April 28, Kain Technology announced that it has signed a strategic agreement with Saifu Pharmaceutical, a one-stop CRO service provider for innovative dru.
The two parties will establish a long-term and strategic business partnership to promote the common development of innovative R&D busine.
It is reported that Kain Technology is a biopharmaceutical company that uses biotechnology as a platform, focuses on the field of viruses and immune diseases, and is committed to providing prevention and treatment solutio.
The industry said that the strategic cooperation between strong and strong can more effectively ensure the rapid advancement of the precise research and development of new drugs, improve the efficiency of new drug research and development for pharmaceutical companies, and save cos.
From the perspective of the cooperation partners sought by pharmaceutical companies this year, innovative drugs, big health, and AI are all areas that pharmaceutical companies focus .
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
